Medicare Expanded Coverage for TAVR Heart Procedures

The policy change allows for earlier treatment of severe aortic stenosis without requiring clinical trial enrollment.

Updated on Sept. 21, 2026 in Heart Disease

Isometric editorial illustration of a metallic heart valve prosthetic, representing the expansion of medical coverage policy. — The Centers for Medicare & Medicaid Services has expanded coverage for TAVR heart procedures, allowing treatment for patients with severe aortic stenosis before symptoms appear. AI Illustration. Upload story photo >

Live Poll

Should Medicare expand coverage for medical procedures before patients show clear symptoms?

The Centers for Medicare & Medicaid Services has finalized a decision to expand coverage for transcatheter aortic valve replacement (TAVR). The updated policy now includes patients with severe aortic stenosis before they begin showing symptoms.

Why it matters

This policy change removes long-standing barriers by eliminating the requirement for symptomatic patients to participate in clinical studies. It reflects a shift toward recognizing the clinical necessity of timely intervention for heart valve disease.

This policy update impacts 2.5 million Americans over age 75 who suffer from severe aortic stenosis. The coverage expansion removes the mandate for symptomatic patients to be enrolled in a clinical study to receive treatment.

The players

Centers for Medicare & Medicaid Services

This federal agency manages the Medicare program and establishes coverage policies for medical procedures across the United States.

Edwards Lifesciences

Headquartered in Irvine, this medical technology company specializes in products for structural heart disease and critical care monitoring.

The details

TAVR is a minimally invasive procedure designed to replace diseased heart valves, offering a critical alternative to traditional open-heart surgery. The new policy provides heart teams across the United States with greater flexibility to make treatment decisions based on individual patient needs.

In July 2025, Edwards Lifesciences petitioned the CMS to reconsider coverage policies.
The CMS finalized the decision to expand TAVR coverage on Sept. 10, 2026.
Edwards Lifesciences is set to present Progress trial results on Nov. 3, 2026.
The company will provide long-term financial guidance in December 2026.

Health Landscape

This decision reflects a broader trend in medical regulation where coverage policies are increasingly aligned with clinical outcomes data rather than restrictive study requirements. It updates the CMS TAVR National Coverage Determination by removing the mandatory clinical trial enrollment.

Patients with severe aortic stenosis may now gain access to minimally invasive valve replacement sooner and without the requirement of joining a clinical study. This policy change empowers heart teams to pursue earlier interventions, potentially improving long-term health outcomes for eligible seniors.

The takeaway

The expansion of Medicare coverage for TAVR procedures marks a significant milestone in making minimally invasive heart care more accessible. Patients diagnosed with severe aortic stenosis should consult with their cardiologists to determine if they now qualify for earlier intervention under the new guidelines.